Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION)
Status: Recruiting
Location: See all (28) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Signed informed consent must be obtained prior to participation in the study.
• Males or females ≥ 18 years of age
• Within 14 days of a successful percutaneous coronary intervention (PCI) or peripheral endovascular intervention (PVI) for symptomatic CAD or lower extremity PAD
• Patients undergoing planned staged interventions are eligible for randomization only after the last planned intervention
Locations
United States
Alabama
Advanced Cardiovascular LLC
RECRUITING
Alexander City
California
Pacific Oaks Medical Group
RECRUITING
Beverly Hills
Valley Clinical Trials
RECRUITING
Covina
Radin Cardiovascular Medical Group, Inc
RECRUITING
Newport Beach
Valley Clinical Trials, LLC - Flourish Research
RECRUITING
Northridge
The Heart Medical Group
RECRUITING
Van Nuys
Interventional Cardiology Medical Group
RECRUITING
West Hills
Florida
Clearwater Cardiovascular Consultants
RECRUITING
Clearwater
Arrow Clinical Trails
RECRUITING
Daytona Beach
Clearwater Cardiovascular and Interventional Consultants- Bardmoor